Biomedical subjects

C Busch

Publications and source records attributed to C Busch.

223 records · Page 13Linked to original sources

PubMedDate not supplied

Blood group antigen expression and prognosis in squamous cell carcinoma of the uterine cervix.

Immunohistochemical staining of invasive squamous cell carcinoma of the uterine cervix, stage IB to IV, with monoclonal antibodies against blood group antigens shows retained expression of the antigen in two thirds of the patients, regardless of stage. The over-all 5 year survival of the 115 patients was 60%, 71% in the antigen positive group, 37% in the antigen negative group. The loss of blood group antigen expression thus implies a worse prognosis in all stages of cervical carcinoma and could be used as a predictive marker.

ABO Blood-Group System↗

PubMedDate not supplied

A grading system for the immunostaining of A, B and H blood group isoantigens in bladder carcinoma.

A test system for the evaluation of ABH blood group isoantigens in bladder carcinoma was developed. A highly standardized staining technique and a set of criteria for the judgement of staining extent and intensity was used. These variables are given numerical values which are multiplied to give a score (0-12) representing a semiquantitative estimate of the ABH-antigen expression. A consecutive series of 230 patients with bladder carcinoma was analyzed, using the test. The correlation between staining scores on the one hand and the tumor grade and stage on the other was assessed. Thirty-three percent of the tumors, irrespective of grade or stage, were completely negative, whereas 15% were positive to the same extent and intensity as normal mucosa. The remaining tumors showed intermediate patterns with respect to both extent and intensity of the expression with a progressive loss of detectable antigens with increasing grade and stage. The material was categorized with respect to the staining patterns for future analysis of the influence on prognostic parameters.

ABO Blood-Group System↗

PubMedDate not supplied

Blood group isoantigen expression during tumour progression of cervical neoplasia.

Twenty-nine cases of microinvasive squamous and 38 cases of progression from preinvasive to invasive carcinoma of the cervix were immunostained with monoclonal antibodies against blood group isoantigens for expression in normal, dysplastic and neoplastic epithelium. The results show a varying staining pattern without correlation to tumour progression, recurrence or survival.

ABO Blood-Group System↗

PubMedDate not supplied

Blood group isoantigen and involucrin expression in cervical intraepithelial neoplasia.

258 patients with dysplastic cervical lesions reclassified as CIN 1-3 and AIM 1-3 and with up to ten years of follow-up were immunostained with monoclonal antibodies against blood group isoantigens and involucrin for expression in normal and dysplastic squamous epithelium. The results show a varied staining pattern with a majority of unchanged staining properties in normal and dysplastic epithelium, the same frequency of increase as decrease in dysplasia and no correlation to progression or recurrence, in variance with previous reports.

ABO Blood-Group System↗

PubMedDate not supplied

Comparative immunohistochemical demonstration of difucosylated carbohydrate antigens and CEA in adenomas and carcinomas of the rectum and rectosigmoid.

The present immunohistochemical investigation reveals that difucosylated carbohydrate antigens (DFCA) are extensively expressed in rectal and rectosigmoid carcinomas while normal mucosa and hyperplastic polyps are mainly negative. The adenomas showed intermediate staining patterns where adenomas with villous structures and moderate-severe dysplasia resembled of carcinomas. CEA was more extensively expressed in both normal, premalignant, and malignant tissue. Thus, DFCA is better than CEA as a discriminator between normal and malignant tissue in the distal large bowel, and may be used in future studies with the intention of advancing our understanding of the neoplastic process and assessing clinical relevance.

Adenoma↗

PubMedDate not supplied

Multi-visceral resection for locally advanced gastric cancer.

Fifty-three of sixty-four patients who underwent gastrectomy for gastric carcinoma presented with advanced gastric cancer. 8 patients underwent palliative gastrectomy. In 17 patients gastrectomy and lymphadenectomy was performed. In 28 patients with locally advanced gastric carcinoma, extended resection was performed. Patients who underwent splenectomy were only included if tumorous adherence to the spleen was present. Hospital mortality and morbidity were 3.6% and 25% in extended resection and 5.9% and 18% in gastrectomy and lymphadenectomy alone. R0 resection was performed in 26/28 and in 16/17 patients, respectively. In R0 (complete) resections the mean one and two-year-survival rates were 64% and 44% in extended resection, and 67% and 47% in gastrectomy and lymphadenectomy. In patients (11) with residual tumour (R1/R2) mean one and two-year-survival rates were 27% and 0%, respectively. If complete resection (R0) is achieved, extended resection for locally advanced gastric carcinoma provides survival time, which is comparable, stage for stage, with survival rates observed after R0 resection for cancer limited to the stomach.

Aged↗

PubMedDate not supplied

Estramustine-binding protein (EMBP) content in four different cell lines and its correlation to estramustine induced metaphase arrest.

It is known that estramustine (EM) accumulates in cells at the G2/M-phase and causes metaphase arrest of various cell types. The inhibitory effect is mediated by interaction with microtubule-associated proteins (MAPs) and/or tubulin. Estramustine-binding protein (EMBP) is a secretory protein which has been found in a number of different tumor cells and has been shown to faciliate the uptake of EM into cells. In this study the efficacy of EM in arresting cells at metaphase was studied, using four different human cell lines; the prostatic cancer cell line DU 145, the breast cancer cell line MDA 231, the colon cancer cell line Colon 320, and the urinary bladder cancer cell line RT4. The cells were incubated with EM at a concentration of 10 micrograms/ml for 24 hours. The data reveal an increase in metaphase arrests in the DU 145 and in Colon 320 cell lines. Both of these cell lines were found to contain high amounts of EMBP using a dot-blot assay. The other two cell lines, MDA 231 and RT4 had undetectable intracellular amounts of the protein and exhibited a low increase in metaphase arrests. The cell lines were analysed regarding S-phase fraction with flow-cytometry (FCM) to exclude the growth rate of the cells as a limiting factor. The results from the FCM confirmed the cytogenic analysis, that is a higher percentage of cells were in the G2/M phase in both the DU 145 and Colon 320 cell line compared to MDA 231 and RT4. EM causes mitotic arrest in those cell lines that contain detectable amounts of EMBP.

Antineoplastic Agents, Hormonal↗